{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:22:56Z","timestamp":1787764976532,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare the safety and efficacy parameters of intravitreal ranibizumab vs intravitreal dexamethasone (IVD) in the treatment of patients with na\u00efve diabetic macular edema (DME) in terms of best-corrected visual acuity (BCVA), central macular thickness (CMT), and possible complications like intraocular pressure (IOP) rise and cataract progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A hospital-based prospective and comparative study of na\u00efve DME patients was conducted between November 2020 and October 2021 with a minimum follow-up (F\/U) period of 6 months. Thirty phakic patients received one dose of IVD implant (Group A) and the other 30 (Group B) received three consecutive monthly doses of ranibizumab. The main exclusion criteria were steroid responders and the presence of ocular inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The mean pre-injection CMT in Group A was 405\u00b5 and reduced to 297.07\u00b5 at 3 months and 278.35\u00b5 at 6 months. Mean increase in logMAR BCVA was 0.55. The mean pre-injection IOP was 16.28 and 17.64 mm of Hg at 6 months. In Group B, the mean pre-injection CMT was 401.07\u00b5 and reduced to 276.1\u00b5 at 3 months and 292.9\u00b5 at 6 months. Mean BCVA increased to 0.37. The mean pre-injection IOP was 17.28 mm Hg and 16.42 mm Hg at 6 months. There was no significant progression of cataract in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The mean decrease in CMT was comparable in both the groups at 6 months F\/U with an improvement of BCVA with no significant IOP fluctuation or cataract progression. Hence, IVD appears to be noninferior to ranibizumab in the treatment of na\u00efve DME.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_767_23","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T01:03:03Z","timestamp":1703206983000},"page":"S106-S110","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of na\u00efve diabetic macular edema"],"prefix":"10.4103","volume":"72","author":[{"given":"Santosh K","family":"Mahapatra","sequence":"first","affiliation":[{"name":"Department of Vitreo-retina Surgery, JPM Rotary Club of Cuttack Eye Hosiptal and Research Institute, Cuttack, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjalika","family":"Parhi","sequence":"additional","affiliation":[{"name":"DNB Resident in Ophthalmology, JPM Rotary Club of Cuttack Eye Hosiptal and Research Institute, Cuttack, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Shree","sequence":"additional","affiliation":[{"name":"DNB Resident in Ophthalmology, JPM Rotary Club of Cuttack Eye Hosiptal and Research Institute, Cuttack, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Mohanty","sequence":"additional","affiliation":[{"name":"Department of Vitreo-retina Surgery, JPM Rotary Club of Cuttack Eye Hosiptal and Research Institute, Cuttack, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"R1-20260508","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"key":"R2-20260508","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jama.298.8.902","article-title":"Management of diabetic retinopathy: A systematic review","volume":"298","author":"Mohamed","year":"2007","journal-title":"JAMA"},{"key":"R3-20260508","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cegh.2019.05.002","article-title":"Awareness of various aspects of diabetes among people visiting tertiary eye care institute in north India","volume":"8","author":"Sharma","year":"2020","journal-title":"Clin Epidemiol Glob Health"},{"key":"R4-20260508","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jama.2010.1111","article-title":"Prevalence of diabetic retinopathy in the United States, 2005-2008","volume":"304","author":"Zhang","year":"2010","journal-title":"JAMA"},{"key":"R5-20260508","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"R6-20260508","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00417-016-3472-1","article-title":"A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema","volume":"255","author":"Callanan","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R7-20260508","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s001250050657","article-title":"Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: Relevance to diabetic retinopathy","volume":"40","author":"Chibber","year":"1997","journal-title":"Diabetologia"},{"key":"R8-20260508","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000364955","article-title":"Role of inflammation in diabetic macular edema","volume":"232","author":"Noma","year":"2014","journal-title":"Ophthalmologica"},{"key":"R9-20260508","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11892-019-1188-4","article-title":"Treatment of diabetic macular edema","volume":"19","author":"Kim","year":"2019","journal-title":"Curr Diab Rep"},{"key":"R10-20260508","first-page":"14","article-title":"Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines. Indian J","volume":"64","author":"Das","year":"2016","journal-title":"Ophthalmol"},{"key":"R11-20260508","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R12-20260508","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ophtha.2005.01.043","article-title":"Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration","volume":"112","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmology"},{"key":"R13-20260508","doi-asserted-by":"crossref","first-page":"633.e1","DOI":"10.1016\/j.ophtha.2005.10.052","article-title":"Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I\/II multicenter, controlled, multidose study","volume":"113","author":"Heier","year":"2006","journal-title":"Ophthalmology"},{"key":"R14-20260508","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"R15-20260508","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"R16-20260508","first-page":"1780","article-title":"Intravitreal dexamethasone implant (Ozurdex) as primary treatment for diabetic macular edema","volume":"55","author":"Cui","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R17-20260508","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4103\/ijo.IJO_620_19","article-title":"Long-term results of a single injection of intravitreal dexamethasone as initial therapy in diabetic macular edema","volume":"68","author":"Mahapatra","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R18-20260508","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"R19-20260508","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajo.2009.06.014","article-title":"Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies","volume":"148","author":"Csaky","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R20-20260508","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2174\/1567201817666201202093637","article-title":"Intravitreal dexamethasone implant versus intravitreal ranibizumab injection for treatment of non-proliferative diabetic macular edema: A prospective, randomized and blinded trial","volume":"18","author":"Mishra","year":"2020","journal-title":"Curr Drug Deliv"},{"key":"R21-20260508","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0974-620X.99368","article-title":"Short-term results of intravitreal dexamethasone implant in the treatment ofrecalcitrant diabetic macular edema: A case series","volume":"5","author":"Rishi","year":"2012","journal-title":"Oman J Ophthalmol"},{"key":"R22-20260508","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/OPTH.S48364","article-title":"Preliminary results of an intravitreal dexamethasone implant (Ozurdex\u00ae) in patients with persistent diabetic macular edema","volume":"7","author":"Pacella","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"R23-20260508","doi-asserted-by":"crossref","first-page":"364143","DOI":"10.1155\/2014\/364143","article-title":"Five-month observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implant","volume":"2014","author":"Zalewski","year":"2014","journal-title":"Mediators Inflamm"},{"key":"R24-20260508","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1002\/pat.4375","article-title":"Overview on natural hydrophilic polysaccharide polymers in drug delivery","volume":"29","author":"Abedini","year":"2018","journal-title":"Polym Adv Technol"},{"key":"R25-20260508","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/pat.4713","article-title":"Biodegradable polymers in gene-silencing technology","volume":"30","author":"Hosseinkhani","year":"2019","journal-title":"Polym Adv Technol"},{"key":"R26-20260508","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2015.03.020","article-title":"Silk fibroin nanoparticle as a novel drug delivery system","volume":"206","author":"Mottaghitalab","year":"2015","journal-title":"J Control Release"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_767_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:54:29Z","timestamp":1787763269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_767_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":26,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_767_23","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"2023-03-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}